Expert on Studies of the PSA Test in Prostate Cancer

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Going back to Swedish data, it has been determined that a midlife PSA test is strongly predictive of long-term risk of aggressive prostate cancer, but a PSA test is not a beneficial test for prostate cancer, explains Vickers.

Studies have also tried to determine how much getting a PSA test advances the time of when a patient has cancer compared to when they show up to the clinic and are diagnosed.